Literature DB >> 2258695

T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity.

J A Gracie1, E M Bolton, C Porteous, J A Bradley.   

Abstract

This study has examined the cellular and humoral responses underlying the rejection of rat renal allografts bearing an isolated RT1Aa class I MHC disparity. RT1Aa disparate kidneys were rejected promptly by high responder RT1u but not by low responder RT1c recipients (median survival time 10 d and greater than 100 d, respectively). The magnitude and phenotype of the cellular infiltrate were similar in rejecting and nonrejecting RT1Aa disparate kidneys. Paradoxically, graft infiltrating cells and spleen cells from RT1u recipients showed minimal ability to lyse donor strain lymphoblasts in vitro, whereas effector cells from RT1c recipients showed modest levels of cytotoxicity. Injection of RT1u rats with MRC OX8 mAb was highly effective at selectively depleting CD8+ cells from graft recipients but had no effect in prolonging the survival of RT1Aa disparate grafts despite the complete absence of CD8+ cells from the graft infiltrate, which included numerous CD4+ T cells and macrophages. RT1u, but not RT1c, recipients mounted a strong alloantibody response against RT1Aa disparate kidneys. Immune serum obtained from RT1u recipients that had rejected a RT1Aa disparate graft was able, when injected into cyclosporin-treated RT1u recipients, to restore their ability to reject a RT1Aa, but not a third-party RT1c, kidney. These results suggest that CD8+ cells in general and CD8+ cytotoxic effector cells in particular are unnecessary for the rapid rejection of RT1Aa class I disparate kidney grafts by high responder RT1u recipients. By implication, CD4+ T cells alone are sufficient to cause prompt rejection of such grafts and they may do so by providing T cell help for the generation of alloantibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258695      PMCID: PMC2188765          DOI: 10.1084/jem.172.6.1547

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  Purification with monoclonal antibody of a predominant leukocyte-common antigen and glycoprotein from rat thymocytes.

Authors:  C A Sunderland; W R McMaster; A F Williams
Journal:  Eur J Immunol       Date:  1979-02       Impact factor: 5.532

2.  Histocompatibility antigens on melanoblasts and hair follicle cells. Cell-localized homograft rejection in allophenic skin grafts.

Authors:  B Mintz; W K Silvers
Journal:  Transplantation       Date:  1970-05       Impact factor: 4.939

3.  A recombinant in the major histocompatibility complex of the rat.

Authors:  G W Butcher; J C Howard
Journal:  Nature       Date:  1977-03-24       Impact factor: 49.962

4.  The mechanism of graft rejection and the concept of antigenic strength.

Authors:  J C Howard; G W Butcher
Journal:  Scand J Immunol       Date:  1981-12       Impact factor: 3.487

5.  The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues.

Authors:  A N Barclay
Journal:  Immunology       Date:  1981-04       Impact factor: 7.397

6.  A repopulation assay for B and T lymphocyte stem cells employing radiation chimaeras.

Authors:  S V Hunt; M H Fowler
Journal:  Cell Tissue Kinet       Date:  1981-07

7.  Immune response genes controlling responsiveness to major transplantation antigens. Specific major histocompatibility complex-linked defect for antibody responses to class I alloantigens.

Authors:  G W Butcher; J R Corvalán; D R Licence; J C Howard
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

8.  Effector cells in allelic H-2 class I-incompatible skin graft rejection.

Authors:  T Ichikawa; E Nakayama; A Uenaka; M Monden; T Mori
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts.

Authors:  B M Hall; S Dorsch; B Roser
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

10.  Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response.

Authors:  H F Dvorak; M C Mihm; A M Dvorak; B A Barnes; E J Manseau; S J Galli
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Perspectives in transplantation immunology 1991.

Authors:  D Kabelitz; M L da Silva Lobo; K Pechhold
Journal:  Klin Wochenschr       Date:  1991-09-03

2.  C6 produced by macrophages contributes to cardiac allograft rejection.

Authors:  Z Qian; B A Wasowska; E Behrens; D L Cangello; J R Brody; S S Kadkol; L Horwitz; J Liu; C Lowenstein; A D Hess; F Sanfilippo; W M Baldwin
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

3.  Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells.

Authors:  Thomas M Conlon; Kourosh Saeb-Parsy; Jennifer L Cole; Reza Motallebzadeh; M Saeed Qureshi; Sylvia Rehakova; Margaret C Negus; Chris J Callaghan; Eleanor M Bolton; J Andrew Bradley; Gavin J Pettigrew
Journal:  J Immunol       Date:  2012-02-08       Impact factor: 5.422

4.  Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.

Authors:  J Fangmann; R Dalchau; J W Fabre
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

5.  Predicting Humoral Alloimmunity from Differences in Donor and Recipient HLA Surface Electrostatic Potential.

Authors:  Dermot H Mallon; Christiane Kling; Matthew Robb; Eva Ellinghaus; J Andrew Bradley; Craig J Taylor; Dieter Kabelitz; Vasilis Kosmoliaptsis
Journal:  J Immunol       Date:  2018-11-14       Impact factor: 5.422

6.  Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.

Authors:  G Benichou; P A Takizawa; C A Olson; M McMillan; E E Sercarz
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.